Novo Nordisk A/S : Victoza(R) label in the US updated to include data showing superior efficacy when compared to Januvia(R) 

Novo Nordisk A/S : Victoza(R) label in the US updated to include datashowing superior efficacy when compared to Januvia(R)

Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

BAGSVAERD, DENMARK, Apr 06, 2012 (Menafn - MARKETWIRE via COMTEX) --Novo Nordisk today announced that the US Food and DrugAdministration (FDA) has approved to update the product label forVictoza(R) (liraglutide [rDNA] injection) to include data showingsuperior blood sugar control and weight reduction when compared toJanuvia(R) (sitagliptin).

Company announcement 22 2012:http://hugin.info/2013/R/1600926/505405.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrantsthat:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1600926]

Further information:

Media:

Mike Rulis
Tel: (45) 3079 3573
Email Contact

Investors:

Klaus Bulow Davidsen
Tel: (45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (45) 3075 3479
Email Contact

In North America:
Ambre Morley
Tel: (1) 609 216-5240
Email Contact

Jannick Lindegaard
Tel: (1) 609 786 4575
Email Contact

SOURCE: Novo Nordisk A/S

http://www2.marketwire.com/mw/emailprcntct?id=23D20CAC5249772D
http://www2.marketwire.com/mw/emailprcntct?id=85B6666D3ED7DD86
http://www2.marketwire.com/mw/emailprcntct?id=A7BB20DE5225B34B
http://www2.marketwire.com/mw/emailprcntct?id=B9F785E5A61413DB
http://www2.marketwire.com/mw/emailprcntct?id=709B98AFF8422EFE
http://www2.marketwire.com/mw/emailprcntct?id=CE5F3089C46CE13C

Copyright 2012 Marketwire, Inc., All rights reserved.